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Abstract
During human immunodeficiency virus type 1 (HIV-1) assembly, the nucleocapsid (NC) and the PTAP motif in p6 of Gag play important roles
in RNA encapsidation and virus release, respectively. We have previously demonstrated that functional complementation occurs between an NC
mutant and a PTAP mutant to rescue viral replication. In this report, we examined the amounts of functional NC and PTAP motif that are required
during virus replication. When NC and PTAP mutants were coexpressed at 5:1, 5:5, and 1:5 ratios, virus titers were rescued at 5%, 51%, and 86%
of the wild-type level, respectively. These results indicate that HIV-1 requires a small amount of functional PTAP motif but far more functional NC
to complete efficient replication. Further analyses reveal that RNA packaging can be significantly rescued in viruses containing a small amount of
functional NC. However, most of the NC proteins must be functional to generate the wild-type level of R-U5 DNA product. Once the R-U5
product is generated, viruses containing half of the functional NC can complete reverse transcription and DNA integration at near-wild-type
efficiency. These results define the quantitative requirements of NC and p6 during HIV-1 replication and provide insights into the requirement for
the development of anti-HIV strategies using NC and p6 as targets.
Published by Elsevier Inc.Keywords: HIV; Nucleocapsid; PTAP late domain; Complementation; ReplicationIntroduction
The major structural proteins of retroviruses are encoded in
the gag gene (Goff, 2007). The gene product, Gag, is first
translated as a polyprotein; in most retroviruses, viral protease
(PR) cleaves the polyprotein to yield the mature proteins during
or soon after virus assembly (Swanstrom and Wills, 1997). Gag
polyproteins containmatrix (MA), capsid (CA), and nucleocapsid
(NC) domains. In some retroviruses, the Gag polyprotein has
additional domains. For example, the Gag polyprotein of human
immunodeficiency virus type 1 (HIV-1) has three additional
regions, spacer peptide 1 (SP1 or p2), located between CA and⁎ Corresponding author. HIV Drug Resistance Program, NCI-Frederick, P. O.
Box B, Building 535, Room 336, Frederick, MD 21702, USA. Fax: +1 301 846
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doi:10.1016/j.virol.2008.02.026NC; SP2 (or p1), located at the C terminus of NC; and p6, located
at the C terminus of Gag (Freed and Martin, 2007).
The Gag polyprotein plays a central role in virus assembly.
Expression of Gag in cells is sufficient to form virus-like
particles (Bennett et al., 1991; Gheysen et al., 1989; Wills and
Craven, 1991); similarly, purified Gag proteins can self-
assemble under suitable conditions (Campbell and Rein,
1999; Campbell and Vogt, 1997). Although in most retroviruses
the assembly of virus-like particles can take place without the
involvement of other viral and cellular components, the
assembly of an infectious virus is far more complex. In this
process, Gag interacts with various viral components, such as
viral RNA, to specifically encapsidate the viral genetic blueprint
(Berkowitz et al., 1996), and other viral proteins, such as Gag–
Pol and Env, to incorporate the viral proteins that are essential
for replication steps (Freed, 1998; Freed and Martin, 1996; Lu
et al., 1995; Murakami and Freed, 2000; Srinivasakumar et al.,
1995). Additionally, Gag interacts with the host cell machinery
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(Garrus et al., 2001; Strack et al., 2003; VerPlank et al., 2001).
Different Gag domains have various functions.MA targets the
Gag proteins to the cellular membrane. In HIV-1, myristoylation
of Gag (Bryant and Ratner, 1990; Gottlinger et al., 1989; Hill
et al., 1996; Ono and Freed, 1999) and the interaction between
MA and cellular factor AP-3 are thought to be important in this
targeting (Dong et al., 2005). CA mediates Gag–Gag interac-
tions, and mutations in CA often cause assembly defects (Craven
et al., 1995; Mammano et al., 1994; Reicin et al., 1995;
Swanstrom andWills, 1997; von Schwedler et al., 2003). TheNC
domain is important in mediating interactions between Gag–Gag
(Bennett et al., 1993; Bowzard et al., 1998; Derdowski et al.,
2004; Ott et al., 2003; Sandefur et al., 2000, 1998) and Gag–
RNA (Berkowitz et al., 1995; Kaye and Lever, 1996; Meric and
Spahr, 1986), and as the mature NC protein, also plays a role in
events during the early phase of viral replication (Buckman et al.,
2003; Thomas et al., 2006). The p6 domain of HIV-1 contains
motifs that interact with viral protein Vpr (Lu et al., 1995) and the
members of the human endosomal sorting pathways. It has been
well documented that the PTAP motif in p6 interacts with host
protein TSG101 (Garrus et al., 2001; Martin-Serrano et al., 2001;
VerPlank et al., 2001). Interference of the Gag–TSG101
interaction, such as by mutating the PTAP motif or expressing
dominant-negative forms of TSG101, can cause virion release
defects (Demirov et al., 2002a,b; Dettenhofer and Yu, 1999;
Garrus et al., 2001; Huang et al., 1995; Martin-Serrano et al.,
2001, 2003; VerPlank et al., 2001). Additionally, sequences near
the C terminus of p6 can interact with host factor ALIX/AIP1
(Chen et al., 2005; Fisher et al., 2007; Strack et al., 2003). These
interactions allow Gag to utilize the host pathway for virion
release.
NC proteins of most retroviruses contain two conserved
features: a region(s) rich in basic residues, and one or two zinc-
binding (zinc finger) motifs. Although the number of zinc finger
motifs varies among retroviruses, they all have the conserved
sequence CX2CX4HX2C (CCHC) (Berg, 1986; Gorelick et al.,
1988). Destroying the conserved zinc finger motifs is detri-
mental to viral replication (Bowles et al., 1993; Gorelick et al.,
1999a, 1993, 1988, 1990; Meric and Goff, 1989; Meric et al.,
1988). Even the replacement of the CCHC motifs with another
conserved zinc finger motif, such as CCCC or CCHH (Gorelick
et al., 1996, 1999b), or another CCHC motif (Bowles et al.,
1993; Gorelick et al., 1993; McGrath et al., 2003) can severely
affect viral replication. Although relatively small in size, NC
plays multiple roles in viral replication. In addition to its role in
Gag–Gag interactions, the NC domain in the Gag polyprotein
mediates specific recognition between Gag and viral RNA
(Berkowitz et al., 1995; Certo et al., 1999; Kaye and Lever,
1998; Zhang and Barklis, 1995). Mutations in NC can lead to a
drastic decrease of viral RNA encapsidation into virions (Bowles
et al., 1993; Gorelick et al., 1999a,b, 1993,1988, 1990; Meric
and Goff, 1989; Meric et al., 1988). In vitro experiments
indicated that the mature NC protein has a chaperone activity
(Levin et al., 2005; Rein et al., 1998; Tsuchihashi and Brown,
1994), and can affect nucleic acid annealing, DNA synthesis and
integration (Brule et al., 2002; Carteau et al., 1999; Cen et al.,2000; Heath et al., 2003; Lapadat-Tapolsky et al., 1997; Lener
et al., 1998; Levin et al., 2005; Rodriguez-Rodriguez et al.,
1995; Rong et al., 2001). In vivo studies indicate that mutations
in NC can affect the efficiency of reverse transcription
(Buckman et al., 2003; Gorelick et al., 1999b; Thomas et al.,
2006) and frequency of reverse transcriptase (RT) template
switching (Zhang et al., 2002). Additionally, NC plays a role
during the integration of viral DNA to form a provirus; although
the exact role and mechanism of how NC affects integration are
unclear, it is thought that NC protects the ends of viral DNA,
thereby allowing efficient integration to occur (Buckman et al.,
2003; Thomas et al., 2006).
Retroviruses can interact with each other through several
different mechanisms, one of which is complementation
following pseudotyping. Pseudotyping refers to the generation
of viral particles containing components from more than one
virus and the use of these components for viral replication. A
common form of pseudotyping is the use of Env proteins from
different viruses. Pseudotyping can occur using other viral
components as well; for example, Gag proteins from two viruses
can coassemble into the same virus particles. Previously, using
an NCmutant and a PTAPmutant, we have shown that these two
HIV-1 Gag mutants can complement each other via coassembly
and complete virus replication (Boyko et al., 2006). In the
current study, we used this established system to address the
quantitative requirements of functional NC and PTAP motif
during HIV-1 assembly and replication. Viral preparations from
NC and PTAP mutants coexpressed at different ratios were
generated and analyzed. We conclude that to achieve the wild-
type virus level of replication efficiency, HIV-1 requires most of
its encapsidated NC proteins but only a small amount of PTAP
motif. NC affects multiple steps of the infection process,
blocking any of these steps can cause a decrease in viral titer.
Additionally, different amounts of functional NC may be
required at various replication steps. To determine the amounts
of NC required, we analyzed viral products during various stages
of the infection process. We conclude that HIV-1 requires less
functional NC proteins during the RNA encapsidation assembly
process than during the events leading to the completion of viral
DNA synthesis. To our knowledge, this is the first quantitative
study of the NC requirement during HIV-1 replication.
Results
Determination of the ratio of functional Gag proteins required
for virus replication
We sought to delineate the amounts of functional NC and
PTAP motif required for efficient HIV-1 replication. To
approach this experimental question, we used two mutants
that each has significant replication defects but at an equal
molar ratio can complement each other's function to complete
the steps required for viral replication. To define the amounts of
functional NC and PTAP motif required for efficient HIV-1
replication in a single round assay, we coexpressed these
mutants at different molar ratios and examined the infectivity of
the resulting viruses.
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Fig. 1A. All of the vectors contained LTRs, cis-acting elements
essential for virus replication, and they express gag–pol, tat,
rev, and a marker gene. The CCHC/CCHC motifs of the NC
mutant (NC⁎) were changed to CCHH/CCCC; this mutation
compromises the specific encapsidation of the viral RNAs and
causes a drastic reduction in the viral titers (Gorelick et al.,Fig. 1. Complementation of two HIV-1 Gag mutants. (A) General structures of
the HIV-1 vectors used for the complementation studies. All vectors are similar in
their general structures but contain different mutations in gag (indicated by the
asterisk) or marker genes. (B) Representative flow cytometry analyses of Hut78/
CCR5 cells infected with wild-type or Gag mutant virus. (C) Representative
flow cytometry analyses of Hut78/CCR5 cells infected with viruses generated
by cotransfection of two mutant or two wild-type vectors at different ratios.1999b). The PTAP motif of the p6 mutant (PTAP⁎) was altered
to LIRL; this mutation leads to a defect in virion release and a
severe decrease in viral titer (Boyko et al., 2006; Demirov et al.,
2002b). The NC⁎ and PTAP⁎ vectors also express a mouse
thy1.2 (thy) and a green fluorescence protein (gfp) gene,
respectively. Vectors WTt and WTg have the same structures as
NC⁎ and PTAP⁎, respectively, except they express the wild-
type gag–pol.
To measure the viral titers generated by these vectors, they
were transfected into 293T cells along with a plasmid that
expresses CCR5-tropic HIV-1 envelope; the resulting viruses
were used to infect a T-cell line, Hut78/CCR5. Infected cells
were analyzed by flow cytometry and viral titers were
determined by the number of cells expressing either the GFP
or Thy marker. As previously observed, compared with vectors
carrying the wild-type gag–pol, the NC⁎ and PTAP⁎ mutants
generated undetectable and drastically decreased viral titers,
respectively (Fig. 1B). We then coexpressed the two mutants,
NC⁎ and PTAP⁎, by transfecting the two plasmids into 293T
cells at 5:1, 5:5, and 1:5 molar ratios. As controls, the two wild-
type vectors, WTt and WTg, were transfected into 293T cells at
5:1, 5:5, and 1:5 ratios. The resulting viruses were harvested and
used to infect Hut78/CCR5 cells; representative flow cytometry
analyses are shown in Fig. 1C. As expected, mixing the wild-
type vectors at any of the three ratios resulted in the generation of
infectious virus that infected large amounts of cells (Fig. 1C,
lower panels). Consistent with our previous observation, at an
equal molar ratio (5:5), the NC⁎ and PTAP⁎ mutants com-
plemented each other and generated infectious viruses that
infected a large number of target cells. Viruses generated from
the 1:5 ratio of NC⁎ and PTAP⁎ mutants also infected a large
portion of the target cells. However, viruses generated from
the 5:1 ratio of NC⁎ and PTAP⁎ mutants, referred to as
5NC⁎+1PTAP⁎, infected only a small portion of the target cells
(Fig. 1C, top left panel). The multiplicities of infection (MOIs)
of these viral preparations were compared with those of the wild-
type controls, and the relative viral titers generated from more
than seven independent experiments are summarized in Fig. 2A.
To probe the mechanisms that caused the low titer generated
by the 5NC⁎+1PTAP⁎ virus, we examined Gag expression in
transfected cells by Western analyses (Fig. 2B) and virion
production in all of the samples by quantifying the amounts of
RT activities (Fig. 2C). Compared with the wild-type controls,
the 5NC⁎+1PTAP⁎ samples have similar Gag expression and
virion production. Virion production in these samples was also
measured by the amounts of CA antigen (p24), which yielded
similar conclusions (data not shown). Therefore, virus produc-
tion was not the main cause for the low virus titers; instead, the
5NC⁎+1PTAP⁎ viruses had lower infectivities compared with
wild-type viruses. To quantify the relative infectivities of
viruses, the MOIs of these viral preparations were normalized
to the RT activities. The infectivity of each combination of the
mutant viruses was compared with the infectivity of its
corresponding wild-type control, which was defined as 100%.
The relative infectivities of these viruses generated from at least
seven independent experiments are summarized in Fig. 2D. The
infectivities of the viruses generated from 5:1, 5:5, and 1:5 ratios
Fig. 3. Virion RNA encapsidation by particles containing wild-type or mutant
Gag proteins. The amount of viral RNA in each virus preparation was
normalized to the values of RT activity (A) or p24 level (B). RNA encapsidation
values for wild-type controls were set as 100%. Results from more than three
independent experiments are summarized; error bars indicate standard errors.
Fig. 2. Virus production, infection titers, and relative infectivities of viruses
containing wild-type or mutant Gag proteins. (A) Infection titers of wild-type or
Gag mutant viruses. Infection was detected by the expression of the marker genes.
TheMOIs of the wild-type controls were set as 100%. (B)Western analysis of Gag
expression in the transfected cells. (C) The level of virus produced from transfected
cells determined by RT activity. RT activities of the wild-type controls were set as
100%. (D) Relative infectivity of wild-type or Gag mutant viruses. The MOI of
each virus was normalized to theRTactivity of the virus preparation, and the values
for the wild-type controls were set as 100%. Results from more than seven
independent experiments are summarized; error bars indicate standard errors.
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wild-type viruses. Therefore, a small portion of the functional
PTAPmotif is sufficient for rescuing virus replication, whereas a
small amount of functional NC is not sufficient for rescuing virus
replication.
Quantitative requirements of Gag polyprotein with a functional
NC domain for encapsidation of viral RNA during the assembly
process
To delineate the block(s) in the viral replication that caused
the low infectivities of the 5NC⁎+1PTAP⁎ virus, we examined
the properties of these viruses. The NC mutant used in this
experiment has a defect in viral RNA encapsidation. It is
possible that the 5NC⁎+1PTAP⁎ viruses have defects in
packaging viral RNAs. We isolated virion RNAs and measured
their amounts by quantitative RT-PCR, then normalized the
amounts of viral RNA to the RT activity (Fig. 3A) or p24 value
(Fig. 3B). In general, the results from the two normalization
procedures are in good agreement, except for the PTAP⁎mutant
samples. The PTAP⁎ mutants have been shown to have lower
RT activity (Dettenhofer and Yu, 1999; Yu et al., 1998), which
could have caused the differences.
The NC⁎ mutant, as previously described (Gorelick et al.,
1999b), encapsidated only approximately 5% of the RNA
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packaged viral RNAs at approximately 40% of the wild-type
level, indicating that a small portion of the Gag with functional
NC is sufficient for rescuing the RNA packaging to this level.
When the amounts of Gag with functional NC increased to 50%
or higher, viral RNAs were packaged at efficiencies equivalent
to that of wild-type viruses.
Strategy used to examine the efficiencies of reverse transcription
in Gag mutant particles
Although RNA packaging was significantly recovered,
5NC⁎+1PTAP⁎ virus had very low viral titers, indicating that
there are additional blocks to viral replication. To explore the
possible blocks in these viruses, we examined their reverse
transcription products. Virus preparations were used to infect
Hut78/CCR5, cellular DNAs were harvested 24 h later, and the
amounts of various viral DNA products were measured by
quantitative real-time PCR. The amounts of a cellular gene,
CCR5, were also measured in each sample as an internal
control; these values were used to determine the levels of DNA
recovery in various samples. Additionally, a negative control
was included in each set of experiments; in this control, a wild-
type virus sample was incubated at 68 °C for 60 min (heat-
inactivated sample) prior to infection. The inactivated viral
sample cannot infect cells nor initiate DNA synthesis, and thus
served as a control for any possible plasmid DNA contamina-
tion in the input virus that may compromise the real-time PCR
quantification. We observed very little DNA contamination; all
negative controls had b6% of the wild-type signals.
Like all retroviruses, HIV-1 uses a tRNA primer annealed to
the primer-binding site near the 5′ end of the viral RNA genome
to initiate reverse transcription (Fig. 4A). Therefore, the first
DNA fragment synthesized is the R-U5 region. After minus-
strand DNA transfer, RT copies U3 and joins the U3-R-U5
regions to reconstitute the LTR, then continues to copy the viral
genome. After plus-strand DNA synthesis, reverse transcription
continues on both strands to complete DNA synthesis. Using
different primer and probe sets, we analyzed and quantified three
DNA products: R-U5, U3-U5, and R-5′UTR. The R-U5 region
is in all viral DNA that successfully initiated DNA synthesis andFig. 4. Effects of mutant Gag proteins on the initiation and progression of HIV-1
reverse transcription. (A) Schematic representation of the reverse transcription
process. A dashed line with an arrow represents the direction of nascent DNA
synthesis; the thin solid line with an arrow and the shaded box represents the
real-time PCR primer and product, respectively. (B) Relative efficiencies of
reverse transcription initiation in mutant viruses. Initiation efficiency was
determined by comparing the amount of viral RNAs in the virion sample with
the amount of R-U5 DNA generated after infection. The initiation efficiency of
wild-type virus was defined as 100%. The initiation efficiency of mutant virus
was compared with that of the wild-type virus to generate the relative efficiency.
The progression of viral DNA synthesis of wild-type, PTAP⁎, and NC⁎ viruses
(C) and of phenotypically mixed viruses containing Gag proteins from two
viruses (D) was analyzed. In the DNA progression studies, the amount of R-U5
product of each sample was defined as 100%, and the amounts of U3–U5 and
the R-5′UTR products were expressed as a percentage of the R-U5 product for
each sample. Results from more than three independent experiments are
summarized; error bars indicate standard errors.copied the first piece of the viral genome. The U3–U5 region is
in viral DNA that carried out minus-strand DNA transfer and
copied the U3, whereas the R-5′UTR region is in viral DNA that
carried out plus-strand DNA transfer and continued DNA
synthesis to join the LTR and 5′UTR. Therefore, by analyzing
Fig. 5. Relative integration efficiency of mutant viruses. Integration efficiency
was calculated by comparing the amount of R-5′UTR product with that of the
Alu-PCR product. The integration efficiency of the wild-type virus was defined
as 100% and that of mutant viruses was expressed as a portion of the wild-type
efficiency. Due to the replication defects of NC⁎ mutant and the sensitivity
limitation of the Alu-PCR assay, the integration efficiency of the NC⁎ mutant
could not be reliably determined. Results from more than three independent
experiments are summarized; error bars indicate standard errors.
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progression of reverse transcription.
Efficiencies of reverse transcription initiation and DNA strand
transfer events for the Gag mutant particles
R-U5 is the first piece of DNA synthesized by RT. The
measurement of R-U5 estimates the combined efficiencies of
events that lead to the initiation of reverse transcription. To
determine the efficiencies of reverse transcription initiation, we
compared the amounts of R-U5 DNA generated after infection
with the amounts of the virion RNA in each virus preparation.
The abilities of the mutant viruses to initiate DNA synthesis
were compared with those of the corresponding wild-type
viruses. NC⁎ and PTAP⁎ mutants initiated their DNA synthesis
at 15% and 25% of the wild-type virus level, respectively
(Fig. 4B). DNA synthesis was initiated at 40% of the wild-type
efficiency for the 5NC⁎+1PTAP⁎ viruses, and at 52% and 97%
of the wild-type efficiency for the 5NC⁎+5PTAP⁎ and the
1NC⁎+5PTAP⁎ viruses, respectively (Fig. 4B). Therefore, both
PTAP⁎ and NC⁎ mutants have significant defects in generating
the R-U5 product; these defects were gradually recovered when
more functional NC proteins were present in the virus.
To examine whether Gag mutants encounter further blocks
during DNA synthesis after the initiation of reverse transcrip-
tion, we also quantified the U3–U5 and R-5′UTR products. Gag
mutants initiated reverse transcription at different efficiencies;
to determine the efficiencies of DNA synthesis progression, the
amount of R-U5 DNA of each virus was defined as 100% and
the amounts of U3–U5 and R-5′UTR of each virus were
expressed as a percentage of R-U5 products (Fig. 4C and D).
Additionally, R-5′UTR copy numbers were multiplied by two
prior to comparison with R-U5 copy numbers. This modifica-
tion was necessary because LTR sequences are duplicated in
viral DNA; thus there are two R-U5 and U3–U5 template
sequences for PCR detection. In contrast, each viral DNA only
has one template sequence for R-5′UTR detection.
The results generated from more than three independent
experiments demonstrated that, once initiated, the progression
of reverse transcription was very efficient in wild-type viruses.
Of the R-U5 DNA detected, 93% contain U3–U5 sequences
and 70% contain R-5′UTR sequences, indicating that these
products have progressed beyond successful minus-strand and
plus-strand DNA transfer events and further elongation,
respectively (Fig. 4C). The progression of reverse transcription
was less efficient in the two Gag mutants. Of the R-U5 DNA
detected in the PTAP⁎ mutant infection, 70% and 54%
contained U3–U5 and R-5′UTR sequences, respectively. Of
the R-U5 DNA detected in the NC⁎ mutant infection, only 52%
and 20% contained U3–U5 and R-5′UTR products, respec-
tively (Fig. 4C).
Although both NC⁎ and PTAP⁎ mutants have defects in
completing reverse transcription, these defects are recovered in
some of the mixed particles. The completion of reverse
transcription was still blocked in 5NC⁎+1PTAP⁎ viruses;
79% and 40% of R-U5 DNA progressed to contain U3–U5 and
R-5′UTR regions, respectively. In contrast, most of the reversetranscription defects were recovered in 5NC⁎+5PTAP⁎ and
1NC⁎+5PTAP⁎ viruses and DNA synthesis had efficiencies
similar to those of wild-type viruses (Fig. 4D).
The effects of mutant Gag proteins on the integration of viral
DNA into the host genome
After reverse transcription, HIV-1 DNA is integrated into the
host genome and forms a provirus. Although integrase (IN) is
the only viral protein required to perform integration reaction in
vitro, it is recognized that other viral proteins, such as NC, also
play an important role in this process (Buckman et al., 2003). To
examine the effects of the mutant Gag proteins on viral
integration, we determined the integration efficiencies during
HIV-1 infection by using an Alu-PCR procedure similar to that
described previously (Butler et al., 2001). In this assay, one
primer anneals to the human repetitive element Alu, and the
other primer anneals to viral sequences. Thus, this procedure
only amplifies integrated DNA— specifically, those proviruses
that integrate close to an Alu element. To evaluate the
integration efficiency between different viruses, we compared
the copy numbers of the Alu-PCR product with those of the R-
5′UTR product to generate an approximate integration
efficiency of each virus preparation. To compare the integration
efficiencies between different viruses, the integration efficiency
of the wild-type viruses was defined as 100%, and the relative
integration efficiencies of the mutant viruses were expressed as
a percentage of the wild-type efficiency. Results from more than
three independent experiments are summarized in Fig. 5.
Of the two mutant viruses we used in this study, we found
that the PTAP⁎ mutants did not exhibit integration defects;
DNA containing R-5′UTR sequences was integrated at
frequencies similar to those of the wild-type viruses. As
shown in Figs. 3 and 4, the NC⁎mutant has multiple defects and
thus generated very little R-5′UTR products during infection.
Compounded with the detection limitation of the Alu-PCR
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determined. However, many of the NC⁎ mutant defects were at
least partially recovered in the NC⁎+PTAP⁎ viruses; therefore,
we were able to measure the integration efficiencies of these
viruses. The 5NC⁎+1 PTAP⁎ viruses integrated at 52% of the
wild-type level, whereas the 5NC⁎+5PTAP⁎ and 1NC⁎+
5PTAP⁎ viruses integrated at the wild-type level. These results
suggest that, similar to many HIV-1 NC mutants, the NC⁎
mutant exhibits defects in integration. These defects can be
rescued by the presence of the wild-type NC proteins.
Taken together, the 5NC⁎+1PTAP⁎ viruses can only
partially overcome multiple defects of the two mutant parents.
However, the 5NC⁎+5PTAP⁎ and 1NC⁎+5PTAP⁎ viruses
were able to efficiently undergo most steps of HIV-1 replication.
These comparisons reveal the quantitative requirements of the
Gag proteins during different stages of viral replication.
Discussion
In this report, we studied the requirements for functional NC
and PTAP domains at various stages of viral replication. Like
many viral proteins, NC is multifunctional, thereby complicat-
ing the analyses of its functions during replication. By
expressing an NC and a PTAP HIV-1 mutant at different ratios,
we studied the level of functional complementation at various
stages of viral replication. Our results indicate that to achieve the
wild-type level of viral replication, HIV-1 requires the function
of most of NC but only a small amount of PTAP. Furthermore,
HIV-1 requires less functional NC during viral RNA packaging
than during events leading to efficient DNA synthesis.
The PTAP⁎ mutant described here has been well studied
(Demirov et al., 2002b; Huang et al., 1995; Yu et al., 1998). The
alteration of PTAP to LIRL prevented the Gag polyprotein from
interacting with TSG101 and resulted in reduced virus
production (Demirov et al., 2002b; Garrus et al., 2001; Huang
et al., 1995; Martin-Serrano et al., 2001). Many of the viruses
produced have immature virion morphology and lower infectiv-
ity (Boyko et al., 2006; Demirov et al., 2002b; Fu et al., 2006;
Huang et al., 1995). We have previously shown that the viral
RNA dimers have lower thermostability than those from wild-
type viruses (Fu et al., 2006). In this study, the replication defect
of the PTAP⁎ mutant is further characterized. Our analyses
indicate that this mutant has defects in events leading to and
during the initiation of viral DNA replication; this result is
consistent with the immature virion morphology observed by
others and us. Interestingly, the PTAP⁎ mutant does not display
many defects after the initiation of viral DNA synthesis; those
viruses that can initiate DNA synthesis can also complete reverse
transcription and integration at near-wild-type efficiency. These
results suggest the possibility that two populations of viruses are
produced by the PTAP⁎ mutants; most of the viruses have
defects in the early steps of viral replication, perhaps during
entry and uncoating. A small population of the mutant viruses
bypassed the early replication defect and those viruses can
continue to complete replication at near-wild-type efficiency.
Late domain mutations in various retroviruses exhibit
different effects of dominance. Although late domain mutantsare dominant in some viruses such as human T-cell leukemia
virus type I (Heidecker et al., 2007), it was previously shown
that a late domain mutant is not dominant in Rous sarcoma virus
(Bennett and Wills, 1999). Similarly, we and others have shown
that a HIV-1 late domain mutant can be rescued by com-
plementation (Boyko et al., 2006; Martin-Serrano et al., 2001).
In this current report, we further demonstrated that only a small
amount of functional PTAP motif is needed to rescue virus
release and titer (Fig. 2A and C); this is in agreement with a
previous study indicating that a portion of the functional PTAP
is needed for the rescue (Martin-Serrano et al., 2001). Addi-
tionally, we have shown that the released viruses have
infectivities similar to those of wild-type viruses (Fig. 2D),
indicating that the defects of virus release and those that led to
DNA synthesis initiation have been relieved by a low amount of
functional PTAP motif.
Much of our knowledge of HIV-1 NC function comes from
mutational analyses. Various NC mutations can affect virus
assembly, RNA packaging, reverse transcription, and integra-
tion. However, how much functional NC is required in each step
of the infection process cannot be addressed in these analyses.
In the current report, we generated viruses with different ratios
of functional NC proteins and analyzed the properties of these
viruses and their infection processes. We found that during the
assembly process, having a small portion of functional NC (one-
sixth) in the virus can significantly recover specific viral RNA
encapsidation. The specific encapsidation of the viral RNA is
mediated by the interactions between Gag and the packaging
signal of the viral RNA. In addition to the specific interaction,
Gag also interacts with RNA in a nonspecific manner. It has
been suggested that RNA serves as a scaffold for Gag
multimerization and virion formation (Campbell and Rein,
1999; Campbell and Vogt, 1997; Muriaux et al., 2001). In the
situation where both wild-type Gag and NC mutant Gag are
present in the cells, the wild-type Gag can interact with viral
RNAs in a sequence-specific manner, thereby facilitating the
subsequent Gag–Gag and nonspecific Gag–RNA interactions
during the virion assembly process. Therefore, it is feasible that
RNA packaging can be rescued by the presence of a small
number of Gag proteins with functional NC.
Our results indicate that both 5NC⁎+1PTAP⁎ and 5NC⁎+
5PTAP⁎ viruses appear to have a replication block during very
early events that lead to the generation of R-U5. Therefore, much
of the functional NC is needed to complete steps required to
efficiently initiate reverse transcription and generate R-U5. NC
mediates part of the Gag–Gag interactions; therefore, mutations
in NC can cause defects in virion assembly, maturation, and
stability (Yovandich et al., 2001). Some of the viruses containing
significant amounts of mutant NC proteins may have these
aforementioned defects, thereby reducing efficiencies in virus
entry and uncoating. Similarly, the initiation of the reverse
transcription may also be affected. The decrease of the R-U5
product is most likely a combination of the defects in both steps.
Due to its chaperone activity, NC has been implicated in minus-
strand and plus-strand DNA transfer reactions (Levin et al.,
2005; Rein et al., 1998). Our results indicated that after the
generation of R-U5 products, the 5NC⁎+5PTAP⁎ virus
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the 5NC⁎+1PTAP⁎ virus preparations have an approximately
two-fold defect. These results suggest that to achieve a wild-type
level of elongation of reverse transcription, including the two
obligatory strand transfer reactions, HIV-1 requires more than
one-sixth, but not more than half, of the functional NC in the
virion. Many NC mutants also have defects in the DNA
integration step (Buckman et al., 2003; Thomas et al., 2006). The
integration efficiencies of the 5NC⁎+1PTAP⁎ virus prepara-
tions, but not the 5NC⁎+5PTAP⁎ or 1NC⁎+5PTAP⁎ virus
preparations, appear to be lower than that of wild-type virus,
suggesting that the function of more than one-sixth of the NC
proteins is needed for the efficient integration reaction.
Despite more than two decades of dedicated efforts, currently
we do not have a cure or an effective vaccine for HIV-1 infection.
The development of antiviral drugs and treatment regimens has
significantly increased life expectancy for those HIV-1 patients
who have access to treatments. The emergence of drug-resistant
HIV-1 variants makes it imperative to develop new antiviral
therapies and drug targets. NC is an essential protein for HIV-1
replication and its functions are important in multiple stages of
viral replication, thereby making NC an attractive target for
antiviral drug development. Our study indicates that in order for
a candidate drug to inhibit HIV-1 replication, it needs to render
most of the NC in the virion nonfunctional, as virions having
approximately half of the functional NC can still replicate at 50%
efficiency. More than 80% of the NC proteins in the virions must
lose their functions to achieve 95% inhibition of viral
replication. Therefore, our study not only reveals the require-
ments of NC at various stages of HIV-1 replication, but also
provides insights into aspects essential to the development of
effective antiviral drugs targeting the HIV-1 NC protein.
Materials and methods
Cell culture, DNA transfection, virus infection, DNA isolation,
and flow cytometry analyses
Human embryonic kidney cell line 293T (DuBridge et al.,
1987) and human T-cell line Hut78/CCR5 (Wu et al., 2002)
were maintained in Dulbecco's modified Eagle's medium and
Roswell Park Memorial Institute-1640 medium, respectively.
Both media were supplemented with 5% fetal calf serum, 5%
calf serum, penicillin (50 U/ml), and streptomycin (50 U/ml).
Additionally, L-glutamine (2 mM) was included in the 293T cell
medium, whereas puromycin (1 μg/ml) and G418 (500 μg/ml)
were included in the Hut78/CCR5 medium. All cultured cells
were maintained in humidified 37 °C incubators with 5% CO2.
DNA transfection was performed using the standard calcium
phosphate method (Sambrook et al., 1989). Salmon sperm DNA
was added to some samples so that each transfection cocktail
contained the same amount of DNA. After incubation at 37 °C
with 3% CO2 for 6–8 h, the transfection mixture was removed
by gently washing the cells four times, each time with 10 ml
of phosphate-buffered saline (PBS) without calcium or mag-
nesium (BioWhittaker). Supernatants from the transfected
cells were harvested 48 h posttransfection, clarified through a0.22-μm-pore-size polyvinylidene fluoride filter to remove
cellular debris, and used for infection or stored at −80 °C for
future analysis. Prior to infection, supernatants were treated
with 10 U/ml of RNase-free DNase I (Roche) for 2 h at 37 °C in
the presence of 10 mM MgCl2 to decrease contamination with
plasmid DNA.
Hut78/CCR5 cells were used as target cells for infection; at
24 h postinfection, a portion of the sample was removed for
DNA isolation and the rest of the cells remained in culture for an
additional 48 h prior to flow cytometry analyses. For the portion
that underwent DNA isolation, cells were passed through a
Ficoll-Paque™ Plus (Amersham Biosciences) cushion by
centrifugation to remove debris, and washed twice with PBS,
and DNAwas isolated using the QIAamp DNA Blood mini kit
(Qiagen) according to the manufacturer's instructions. To
determine the level of virus infection, cells were stained with
allophycocyanin (APC)-conjugated α-Thy1.2 antibody
(eBioscience), flow cytometry analyses were performed on a
FACSCalibur system (Becton Dickinson Biosciences), and data
were analyzed using the FlowJo software (Tree Star). Infected
cells were identified by the expression of GFP or Thy 1.2
marker. The number of total live cells (Y) and infected cells (Z)
were used to calculate multiplicities of infection (MOI) as log (1
−Z /Y) / log [(Y−1) /Y] /Y, based on Poisson distribution as
previously described (Rhodes et al., 2005).
Viral RNA quantification and real-time PCR analyses of viral
DNA
Virion RNAwas isolated as previously described with minor
modifications (Thomas et al., 2006). Briefly, virions were
incubated with lysis buffer (50 mM Tris, pH 7.4, 10 mM EDTA,
1% w/v SDS, 100 mM NaCl, 50 µg/ml tRNA, 100 µg/ml
proteinase K), extracted twice with phenol/chloroform/isoamyl
alcohol (25:24:1), and precipitated with ethanol. RNA was
pelleted at 21,000 ×g for 30 min and treated with RQ1 RNase-
free DNase (Promega) to remove plasmid DNA contamination.
After the DNase was inactivated by adding 4 M guanidinium
isothiocyanate, RNA was precipitated again with ethanol, and
resuspended in diethylpyrocarbonate-treated water with 1 mM
dithiothreitol and 1 U/µl RNaseOUT (Invitrogen).
Quantitative reverse transcription PCR (RT-PCR) was
performed as previously described (Cline et al., 2005). Viral
RNA was serially diluted to ensure the linearity of RT-PCR
quantification. RT-PCR was carried out using a two-step
protocol in 96-well optical plates. The RT reaction was
incubated at 25 °C for 15 min, 42 °C for 40 min, 85 °C for
10 min, and 25 °C for 30 min. After the reverse transcription
step, PCR was carried out by first incubating the reaction at
95 °C for 10 min, then 45 cycles of 95 °C for 15 s and 60 °C for
1 min. RNA transcripts generated from a KpnI-digested
pRB1334 plasmid were used as a standard for RNA quantifica-
tion. In this assay, primers and probe anneal to sequences in the
gag gene of the viral RNA (Buckman et al., 2003).
Viral DNA synthesis was measured by real-time PCR as
previously described (Buckman et al., 2003). To monitor the
possible contamination of plasmid DNA, in each experiment a
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virus and the resulting sample was measured in parallel with the
other samples. Cellular DNAwas diluted 3- to 10-fold in buffer
containing 10 mM Tris and 0.5 mM EDTA (pH 8.3); some
samples were digested with 0.5 U of DpnI for 3 h prior to
analyses. Relative recovery of cellular DNAwas determined by
measuring the copy numbers of the CCR5 gene in a given
sample. Previously described primers, probes, standards, and
protocol were used to quantify R-U5, U3–U5, and R-5′UTR
(Buckman et al., 2003) and CCR5 (Thomas et al., 2006).
The amount of provirus integration was measured by Alu-
PCR similar to the method previously described by Bushman
et al. (Butler et al., 2001). DNA isolated from a HOS cell line,
IH624-1, referred to as IS DNA, was used as a standard for Alu-
PCR and provirus integration (Thomas et al., 2006). IH624-1
consists of a pool of cells infected with an HIV-1 vector. IS
DNAwas serially diluted with Hut78/CCR5 cellular DNA such
that each dilution had the same copy number of a cellular gene,
CCR5, and different numbers of proviruses. Proviral copies in
IS DNA dilutions were determined by measuring the amount of
R-5′UTR.
RT activity assay and Western analyses
RTactivity and viral capsid (p24) amounts were determined to
measure virion production. For the RT assay, viruses were
pelleted at 50,000 ×g for 1 h at 4 °C and resuspended in PBS. RT
activity was determined using the Quan-T-RT scintillation
proximity assay (Amersham Biosciences) according to the
manufacturer's instructions. A series of increasing virus amounts
was analyzed to ensure the linearity of the assay. The amount of
viral p24 was detected using the Alliance HIV p24 ELISA kit
(PerkinElmer) according to the manufacturer's instructions.
To examine cellular Gag expression, transfected 293T cells
were washed twice in phosphate-buffered saline, lysed in lysis
buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% Triton-100), and clarified by centrifugation. A portion of the
lysate from each sample was loaded on a 12% Tris–glycine gel,
separated by gel electrophoresis, and transferred to an Immobi-
lon-FL polyvinylidene difluoride membrane (Millipore). The
membrane was probed with a human anti-HIV-1 antisera
obtained from NIH AIDS Research and Reference Reagents
Program, followed by donkey anti-human antibodies labeled
with the IRDye800 fluorophore at dilution of 1:10,000 (Rock-
land). Images of the analyses were captured using the Odyssey
infrared imaging system (Li-Cor).
Acknowledgments
We thank Anne Arthur for expert editorial help, James
Thomas and Tamyo Mbisa for their advice on the real-time PCR
detections, Gisela Heidecker for discussions, and Eric Freed for
his kind gift of plasmid.
This research was supported in part by the Intramural
Research Program of the NIH, National Cancer Institute, Center
for Cancer Research, and in part by NCI contract no. N01-CO-
12400. The content of this publication does not necessarily reflectthe views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products,
or organization imply endorsement by the U.S. government.
References
Bennett, R.P., Wills, J.W., 1999. Conditions for copackaging Rous sarcoma
virus and murine leukemia virus Gag proteins during retroviral budding.
J. Virol. 73 (3), 2045–2051.
Bennett, R.P., Rhee, S., Craven, R.C., Hunter, E., Wills, J.W., 1991. Amino
acids encoded downstream of gag are not required by Rous sarcoma virus
protease during gag-mediated assembly. J. Virol. 65 (1), 272–280.
Bennett, R.P., Nelle, T.D., Wills, J.W., 1993. Functional chimeras of the Rous
sarcoma virus and human immunodeficiency virus gag proteins. J. Virol. 67
(11), 6487–6498.
Berg, J.M., 1986. Potential metal-binding domains in nucleic acid binding
proteins. Science 232 (4749), 485–487.
Berkowitz, R.D., Ohagen, A., Hoglund, S., Goff, S.P., 1995. Retroviral
nucleocapsid domains mediate the specific recognition of genomic viral
RNAs by chimeric Gag polyproteins during RNA packaging in vivo. J. Virol.
69 (10), 6445–6456.
Berkowitz, R., Fisher, J., Goff, S.P., 1996. RNApackaging. Curr. Top.Microbiol.
Immunol. 214, 177–218.
Bowles, N.E., Damay, P., Spahr, P.F., 1993. Effect of rearrangements and
duplications of the Cys-His motifs of Rous sarcoma virus nucleocapsid
protein. J. Virol. 67 (2), 623–631.
Bowzard, J.B., Bennett, R.P., Krishna, N.K., Ernst, S.M., Rein, A., Wills, J.W.,
1998. Importance of basic residues in the nucleocapsid sequence for retrovirus
Gag assembly and complementation rescue. J. Virol. 72 (11), 9034–9044.
Boyko, V., Leavitt, M., Gorelick, R., Fu, W., Nikolaitchik, O., Pathak, V.K.,
Nagashima, K., Hu, W.S., 2006. Coassembly and complementation of Gag
proteins from HIV-1 and HIV-2, two distinct human pathogens. Mol. Cell.
23 (2), 281–287.
Brule, F., Marquet, R., Rong, L., Wainberg, M.A., Roques, B.P., Le Grice, S.F.,
Ehresmann, B., Ehresmann, C., 2002. Structural and functional properties of
the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid
protein: comparison with the heat-annealed complex. Rna 8 (1), 8–15.
Bryant,M., Ratner, L., 1990.Myristoylation-dependent replication and assembly
of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. U. S. A. 87 (2),
523–527.
Buckman, J.S., Bosche, W.J., Gorelick, R.J., 2003. Human immunodeficiency
virus type 1 nucleocapsid Zn(2+) fingers are required for efficient reverse
transcription, initial integration processes, and protection of newly
synthesized viral DNA. J. Virol. 77 (2), 1469–1480.
Butler, S.L., Hansen, M.S., Bushman, F.D., 2001. A quantitative assay for HIV
DNA integration in vivo. Nat. Med. 7 (5), 631–634.
Campbell, S., Vogt, V.M., 1997. In vitro assembly of virus-like particles with
Rous sarcoma virus Gag deletion mutants: identification of the p10 domain
as a morphological determinant in he formation of spherical particles.
J. Virol. 71 (6), 4425–4435.
Campbell, S., Rein, A., 1999. In vitro assembly properties of human
immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol.
73 (3), 2270–2279.
Carteau, S., Gorelick, R.J., Bushman, F.D., 1999. Coupled integration of human
immunodeficiency virus type 1 cDNA ends by purified integrase in vitro:
stimulation by the viral nucleocapsid protein. J. Virol. 73 (8), 6670–6679.
Cen, S., Khorchid, A., Gabor, J., Rong, L., Wainberg, M.A., Kleiman, L., 2000.
Roles of Pr55(gag) and NCp7 in tRNA(3) (Lys) genomic placement and the
initiation step of reverse transcription in human immunodeficiency virus
type 1. J. Virol. 74 (22), 10796–10800.
Certo, J.L., Kabdulov, T.O., Paulson, M.L., Anderson, J.A., Hu, W.S., 1999. The
nucleocapsid domain is responsible for the ability of spleen necrosis virus
(SNV) Gag polyprotein to package both SNV and murine leukemia virus
RNA. J. Virol. 73 (11), 9170–9177.
Chen, C., Vincent, O., Jin, J., Weisz, O.A., Montelaro, R.C., 2005. Functions of
early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious
anemia virus budding. J. Biol. Chem. 280 (49), 40474–40480.
548 O.A. Nikolaitchik et al. / Virology 375 (2008) 539–549Cline, A.N., Bess, J.W., Piatak Jr., M., Lifson, J.D., 2005. Highly sensitive SIV
plasma viral load assay: practical considerations, realistic performance
expectations, and application to reverse engineering of vaccines for AIDS.
J. Med. Primatol. 34 (5–6), 303–312.
Craven, R.C., Leure-duPree, A.E., Weldon Jr., R.A., Wills, J.W., 1995. Genetic
analysis of the major homology region of the Rous sarcoma virus Gag
protein. J. Virol. 69 (7), 4213–4227.
Demirov, D.G., Ono, A., Orenstein, J.M., Freed, E.O., 2002a. Overexpression of
the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late
domain function. Proc. Natl. Acad. Sci. U. S. A. 99 (2), 955–960.
Demirov, D.G., Orenstein, J.M., Freed, E.O., 2002b. The late domain of human
immunodeficiency virus type 1 p6 promotes virus release in a cell type-
dependent manner. J. Virol. 76 (1), 105–117.
Derdowski, A., Ding, L., Spearman, P., 2004. A novel fluorescence resonance
energy transfer assay demonstrates that the human immunodeficiency virus
type 1 Pr55Gag I domain mediates Gag–Gag interactions. J. Virol. 78 (3),
1230–1242.
Dettenhofer, M., Yu, X.F., 1999. Proline residues in human immunodeficiency
virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication
and virion incorporation of Pol proteins. J. Virol. 73 (6), 4696–4704.
Dong, X., Li, H., Derdowski, A., Ding, L., Burnett, A., Chen, X., Peters, T.R.,
Dermody, T.S., Woodruff, E., Wang, J.J., Spearman, P., 2005. AP-3 directs
the intracellular trafficking of HIV-1 Gag and plays a key role in particle
assembly. Cell 120 (5), 663–674.
DuBridge, R.B., Tang, P., Hsia, H.C., Leong, P.M., Miller, J.H., Calos, M.P.,
1987. Analysis of mutation in human cells by using an Epstein–Barr virus
shuttle system. Mol. Cell. Biol. 7 (1), 379–387.
Fisher, R.D., Chung, H.Y., Zhai, Q., Robinson, H., Sundquist, W.I., Hill, C.P.,
2007. Structural and biochemical studies of ALIX/AIP1 and its role in
retrovirus budding. Cell 128 (5), 841–852.
Freed, E.O., 1998. HIV-1 gag proteins: diverse functions in the virus life cycle.
Virology 251 (1), 1–15.
Freed, E.O., Martin, M.A., 1996. Domains of the human immunodeficiency
virus type 1 matrix and gp41 cytoplasmic tail required for envelope
incorporation into virions. J. Virol. 70 (1), 341–351.
Freed, E.O., Martin, M.A., 2007. “Retroviridae: the retroviruses and their
replication.” In: David, P.M.H., Knipes, M. (Eds.), fifth ed. Fields Virology,
II. Lippincott William and Wilkins, Piladelphia, PA, USA. II.
Fu, W., Dang, Q., Nagashima, K., Freed, E.O., Pathak, V.K., Hu, W.S., 2006.
Effects of Gag mutation and processing on retroviral dimeric RNA
maturation. J. Virol. 80 (3), 1242–1249.
Garrus, J.E., von Schwedler, U.K., Pornillos, O.W., Morham, S.G., Zavitz, K.H.,
Wang,H.E.,Wettstein, D.A., Stray, K.M., Cote,M., Rich, R.L.,Myszka, D.G.,
Sundquist, W.I., 2001. Tsg101 and the vacuolar protein sorting pathway are
essential for HIV-1 budding. Cell 107 (1), 55–65.
Gheysen, D., Jacobs, E., de Foresta, F., Thiriart, C., Francotte,M., Thines, D., De
Wilde, M., 1989. Assembly and release of HIV-1 precursor Pr55gag virus-
like particles from recombinant baculovirus-infected insect cells. Cell 59 (1),
103–112.
Goff, S.P., 2007. “Retroviridae: the retroviruses and their replication.” In: David,
P.M.H., Knipes, M. (Eds.), fifth ed. Fields Virology, II. Lippincott William
and Wilkins, Piladelphia, PA, USA. II.
Gorelick, R.J., Henderson, L.E., Hanser, J.P., Rein, A., 1988. Point mutants of
Moloney murine leukemia virus that fail to package viral RNA: evidence for
specific RNA recognition by a “zinc finger-like” protein sequence. Proc.
Natl. Acad. Sci. U. S. A. 85 (22), 8420–8424.
Gorelick, R.J., Nigida Jr., S.M., Bess Jr., J.W., Arthur, L.O., Henderson, L.E.,
Rein, A., 1990. Noninfectious human immunodeficiency virus type 1
mutants deficient in genomic RNA. J. Virol. 64 (7), 3207–3211.
Gorelick, R.J., Chabot, D.J., Rein, A., Henderson, L.E., Arthur, L.O., 1993.
The two zinc fingers in the human immunodeficiency virus type 1
nucleocapsid protein are not functionally equivalent. J. Virol. 67 (7),
4027–4036.
Gorelick, R.J., Chabot, D.J., Ott, D.E., Gagliardi, T.D., Rein, A., Henderson, L.E.,
Arthur, L.O., 1996. Genetic analysis of the zinc finger in the Moloney murine
leukemia virus nucleocapsid domain: replacement of zinc-coordinating
residues with other zinc-coordinating residues yields noninfectious particles
containing genomic RNA. J. Virol. 70 (4), 2593–2597.Gorelick, R.J., Benveniste, R.E., Gagliardi, T.D., Wiltrout, T.A., Busch, L.K.,
Bosche, W.J., Coren, L.V., Lifson, J.D., Bradley, P.J., Henderson, L.E.,
Arthur, L.O., 1999a. Nucleocapsid protein zinc-finger mutants of simian
immunodeficiency virus strain mne produce virions that are replication
defective in vitro and in vivo. Virology 253 (2), 259–270.
Gorelick, R.J., Gagliardi, T.D., Bosche, W.J., Wiltrout, T.A., Coren, L.V.,
Chabot, D.J., Lifson, J.D., Henderson, L.E., Arthur, L.O., 1999b. Strict
conservation of the retroviral nucleocapsid protein zinc finger is strongly
influenced by its role in viral infection processes: characterization of HIV-1
particles containing mutant nucleocapsid zinc-coordinating sequences.
Virology 256 (1), 92–104.
Gottlinger, H.G., Sodroski, J.G., Haseltine, W.A., 1989. Role of capsid
precursor processing and myristoylation in morphogenesis and infectivity of
human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 86
(15), 5781–5785.
Heath, M.J., Derebail, S.S., Gorelick, R.J., DeStefano, J.J., 2003. Differing roles
of the N- and C-terminal zinc fingers in human immunodeficiency virus
nucleocapsid protein-enhanced nucleic acid annealing. J. Biol. Chem. 278
(33), 30755–30763.
Heidecker, G., Lloyd, P.A., Soheilian, F., Nagashima, K., Derse, D., 2007. The
role of WWP1–Gag interaction and Gag ubiquitination in assembly and
release of human T-cell leukemia virus type 1. J. Virol. 81 (18), 9769–9777.
Hill, C.P., Worthylake, D., Bancroft, D.P., Christensen, A.M., Sundquist, W.I.,
1996. Crystal structures of the trimeric human immunodeficiency virus type
1 matrix protein: implications for membrane association and assembly. Proc.
Natl. Acad. Sci. U. S. A. 93 (7), 3099–3104.
Huang, M., Orenstein, J.M., Martin, M.A., Freed, E.O., 1995. p6Gag is required
for particle production from full-length human immunodeficiency virus type
1 molecular clones expressing protease. J. Virol. 69 (11), 6810–6818.
Kaye, J.F., Lever, A.M., 1996. trans-acting proteins involved in RNA
encapsidation and viral assembly in human immunodeficiency virus type
1. J. Virol. 70 (2), 880–886.
Kaye, J.F., Lever, A.M., 1998. Nonreciprocal packaging of human immuno-
deficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of
Gag in RNA encapsidation. J. Virol. 72 (7), 5877–5885.
Lapadat-Tapolsky, M., Gabus, C., Rau, M., Darlix, J.L., 1997. Possible roles of
HIV-1 nucleocapsid protein in the specificity of proviral DNA synthesis and
in its variability. J. Mol. Biol. 268 (2), 250–260.
Lener, D., Tanchou, V., Roques, B.P., Le Grice, S.F., Darlix, J.L., 1998.
Involvement of HIV-I nucleocapsid protein in the recruitment of reverse
transcriptase into nucleoprotein complexes formed in vitro. J. Biol. Chem.
273 (50), 33781–33786.
Levin, J.G., Guo, J., Rouzina, I., Musier-Forsyth, K., 2005. Nucleic acid
chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse
transcription and molecular mechanism. Prog. Nucleic Acid Res. Mol. Biol.
80, 217–286.
Lu, Y.L., Bennett, R.P., Wills, J.W., Gorelick, R., Ratner, L., 1995. A leucine
triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation
into human immunodeficiency virus type 1 particles. J. Virol. 69 (11),
6873–6879.
Mammano, F., Ohagen, A., Hoglund, S., Gottlinger, H.G., 1994. Role of the
major homology region of human immunodeficiency virus type 1 in virion
morphogenesis. J. Virol. 68 (8), 4927–4936.
Martin-Serrano, J., Zang, T., Bieniasz, P.D., 2001. HIV-1 and Ebola virus
encode small peptide motifs that recruit Tsg101 to sites of particle assembly
to facilitate egress. Nat. Med. 7 (12), 1313–1319.
Martin-Serrano, J., Zang, T., Bieniasz, P.D., 2003. Role of ESCRT-I in retroviral
budding. J. Virol. 77 (8), 4794–4804.
McGrath, C.F., Buckman, J.S., Gagliardi, T.D., Bosche, W.J., Coren, L.V.,
Gorelick, R.J., 2003. Human cellular nucleic acid-binding protein Zn2+
fingers support replication of human immunodeficiency virus type 1 when
they are substituted in the nucleocapsid protein. J. Virol. 77 (15), 8524–8531.
Meric, C., Spahr, P.F., 1986. Rous sarcoma virus nucleic acid-binding protein
p12 is necessary for viral 70S RNA dimer formation and packaging. J. Virol.
60 (2), 450–459.
Meric, C., Goff, S.P., 1989. Characterization of Moloney murine leukemia virus
mutants with single-amino-acid substitutions in the Cys-His box of the
nucleocapsid protein. J. Virol. 63 (4), 1558–1568.
549O.A. Nikolaitchik et al. / Virology 375 (2008) 539–549Meric, C., Gouilloud, E., Spahr, P.F., 1988. Mutations in Rous sarcoma virus
nucleocapsid protein p12 (NC): deletions of Cys-His boxes. J. Virol. 62 (9),
3328–3333.
Murakami, T., Freed, E.O., 2000. Genetic evidence for an interaction between
human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41
cytoplasmic tail. J. Virol. 74 (8), 3548–3554.
Muriaux, D., Mirro, J., Harvin, D., Rein, A., 2001. RNA is a structural element
in retrovirus particles. Proc. Natl. Acad. Sci. U. S. A. 98 (9), 5246–5251.
Ono, A., Freed, E.O., 1999. Binding of human immunodeficiency virus type 1
Gag to membrane: role of the matrix amino terminus. J. Virol. 73 (5),
4136–4144.
Ott, D.E., Coren, L.V., Chertova, E.N., Gagliardi, T.D., Nagashima, K., Sowder
2nd, R.C., Poon, D.T., Gorelick, R.J., 2003. Elimination of protease activity
restores efficient virion production to a human immunodeficiency virus type
1 nucleocapsid deletion mutant. J. Virol. 77 (10), 5547–5556.
Reicin, A.S., Paik, S., Berkowitz, R.D., Luban, J., Lowy, I., Goff, S.P., 1995.
Linker insertion mutations in the human immunodeficiency virus type 1 gag
gene: effects on virion particle assembly, release, and infectivity. J. Virol. 69
(2), 642–650.
Rein, A., Henderson, L.E., Levin, J.G., 1998. Nucleic-acid-chaperone activity of
retroviral nucleocapsid proteins: significance for viral replication. Trends
Biochem. Sci. 23 (8), 297–301.
Rhodes, T.D., Nikolaitchik, O., Chen, J., Powell, D., Hu, W.S., 2005. Genetic
recombination of human immunodeficiency virus type 1 in one round of
viral replication: effects of genetic distance, target cells, accessory genes,
and lack of high negative interference in crossover events. J. Virol. 79 (3),
1666–1677.
Rodriguez-Rodriguez, L., Tsuchihashi, Z., Fuentes, G.M., Bambara, R.A., Fay,
P.J., 1995. Influence of human immunodeficiency virus nucleocapsid protein
on synthesis and strand transfer by the reverse transcriptase in vitro. J. Biol.
Chem. 270 (25), 15005–15011.
Rong, L., Liang, C., Hsu,M., Guo, X., Roques, B.P.,Wainberg,M.A., 2001. HIV-
1 nucleocapsid protein and the secondary structure of the binary complex
formed between tRNA(Lys.3) and viral RNA template play different roles
during initiation of (−) strand DNA reverse transcription. J. Biol. Chem. 276
(50), 47725–47732.
Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular Cloning: A
Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold
Spring Harbor, N.Y.
Sandefur, S., Varthakavi, V., Spearman, P., 1998. The I domain is required for
efficient plasma membrane binding of human immunodeficiency virus type
1 Pr55Gag. J. Virol. 72 (4), 2723–2732.
Sandefur, S., Smith, R.M., Varthakavi, V., Spearman, P., 2000. Mapping and
characterization of the N-terminal I domain of human immunodeficiency
virus type 1 Pr55(Gag). J. Virol. 74 (16), 7238–7249.Srinivasakumar, N., Hammarskjold, M.L., Rekosh, D., 1995. Characterization
of deletion mutations in the capsid region of human immunodeficiency virus
type 1 that affect particle formation and Gag–Pol precursor incorporation.
J. Virol. 69 (10), 6106–6114.
Strack, B., Calistri, A., Craig, S., Popova, E., Gottlinger, H.G., 2003. AIP1/
ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus
budding. Cell 114 (6), 689–699.
Swanstrom, R., Wills, J.W., 1997. Synthesis, assembly, and processing of
viral proteins. In: Coffin, J.M., Hughes, S.H., Varmus, H.E. (Eds.), Retro-
viruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y,
pp. 263–334.
Thomas, J.A., Gagliardi, T.D., Alvord, W.G., Lubomirski, M., Bosche, W.J.,
Gorelick, R.J., 2006. Human immunodeficiency virus type 1 nucleocapsid
zinc-finger mutations cause defects in reverse transcription and integration.
Virology 353 (1), 41–51.
Tsuchihashi, Z., Brown, P.O., 1994. DNA strand exchange and selective DNA
annealing promoted by the human immunodeficiency virus type 1
nucleocapsid protein. J. Virol. 68 (9), 5863–5870.
VerPlank, L., Bouamr, F., LaGrassa, T.J., Agresta, B., Kikonyogo, A., Leis, J.,
Carter, C.A., 2001. Tsg101, a homologue of ubiquitin-conjugating (E2)
enzymes, binds the L domain in HIV type 1 Pr55(Gag). Proc. Natl. Acad.
Sci. U. S. A. 98 (14), 7724–7729.
von Schwedler, U.K., Stray, K.M., Garrus, J.E., Sundquist, W.I., 2003.
Functional surfaces of the human immunodeficiency virus type 1 capsid
protein. J. Virol. 77 (9), 5439–5450.
Wills, J.W., Craven, R.C., 1991. Form, function, and use of retroviral gag
proteins. Aids 5 (6), 639–654.
Wu, L., Martin, T.D., Vazeux, R., Unutmaz, D., KewalRamani, V.N., 2002.
Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-
SIGN interactions with ICAM-3 do not promote human immunodeficiency
virus type 1 transmission. J. Virol. 76 (12), 5905–5914.
Yovandich, J.L., Chertova, E.N., Kane, B.P., Gagliardi, T.D., Bess Jr., J.W.,
Sowder 2nd, R.C., Henderson, L.E., Gorelick, R.J., 2001. Alteration of zinc-
binding residues of simian immunodeficiency virus p8(NC) results in subtle
differences in gag processing and virion maturation associated with
degradative loss of mutant NC. J. Virol. 75 (1), 115–124.
Yu, X.F., Dawson, L., Tian, C.J., Flexner, C., Dettenhofer, M., 1998. Mutations
of the human immunodeficiency virus type 1 p6Gag domain result in
reduced retention of Pol proteins during virus assembly. J. Virol. 72 (4),
3412–3417.
Zhang, Y., Barklis, E., 1995. Nucleocapsid protein effects on the specificity of
retrovirus RNA encapsidation. J. Virol. 69 (9), 5716–5722.
Zhang, W.H., Hwang, C.K., Hu, W.S., Gorelick, R.J., Pathak, V.K., 2002. Zinc
finger domain of murine leukemia virus nucleocapsid protein enhances the
rate of viral DNA synthesis in vivo. J. Virol. 76 (15), 7473–7484.
